Top Story
Upbeat Sentiment and Undeployed Capital Prop-Up APAC’s Recovery, says ULI’s Emerging Trends in Real Estate® Report
Tokyo Overtakes Singapore as Top-Ranked Investment Prospect
December 7, 2021
Analysis of Asia Pacific life sciences sector finds strong structural growth but distinctive characteristics that challenge assumptions and require both sector expertise and regional understanding.
For more information, email [email protected].
HONG KONG (7 December, 2021) – A report from the Urban Land Institute (ULI) finds that a genuine opportunity exists for the real estate industry to engage in the structural growth of the life sciences sector in the Asia Pacific region, providing investors with yield and anti-cyclical diversification.
The report, Understanding the life sciences sector in Asia Pacific: the case for investment, finds that the life sciences sector is not yet well understood by the real estate industry in Asia Pacific or recognised as a distinct investment sector. Creating a less fragmented and more mature life sciences real estate (LSRE) market, as has been achieved in the United States, requires transparency and knowledge sharing.
The report recommends that the APAC real estate sector:
The report assesses which cities and countries are best placed for investment in life sciences real estate. The locations with the best functioning innovation ecosystems are identified as Singapore and Hong Kong, followed by Mainland China and Japan. South Korea and Australia are ranked fifth and sixth respectively. Choice of location for companies and employees will also depend on the availability of funding for life sciences. In terms of absolute expenditure on research and development (R&D), China leads by some margin, but Singapore and South Korea come top by total spend on R&D per capita.
These factors are reflected in the top three destinations for investment in Asia Pacific LSRE over the period Q3 2015 to Q3 2021, which are China, South Korea and Japan. The main countries of origin for investors in Asia Pacific LSRE are, likewise, China, South Korea and Japan. The principal buyers of LSRE are developers (28%), fund managers (26%) and operators (24%). Four-fifths of those who transacted in this period did one deal only, which suggests that the market is quite fragmented.
The report presents insights gained from market participants through a survey of ULI members in the Asia Pacific region. Over half (57%) of respondents were interested in the life sciences sector because of competitive risk adjusted returns compared with other asset classes and the potential for capital growth. The greatest challenges to investment were lack of data to make informed decisions (43%), lack of experience (43%) and lack of suitable real estate (43%).
The trend towards urbanisation of the life sciences sector seen in some of the North American and European cities is less evident in the Asia Pacific region, where the preference remains with purpose-built parks, precincts and suburban locations. Participants showed a clear preference for scale, being most keen to invest in mixed-use life science campus (37%) and entire science parks or similar large scale developments (32%). The most productive types of location for life sciences were identified by respondents as business parks with some science/R&D facilities (43%), science parks (28%), urban clusters (14%) and university space (14%).
“The real estate community is playing an active role around the globe in supporting the ecosystems critical to the life sciences business life cycle,” said David Faulkner, president of the ULI Asia Pacific region. “Demographic trends promise strong and sustained growth for life sciences and that ought to present an attractive proposition for real estate investors and developers. Making the most of that opportunity will require industry knowledge and specialised real estate expertise, as well as the usual local market knowledge.”
“The most successful approaches will offer flexibility and collaboration while looking forward to the evolving requirements of life sciences tenants. The APAC real estate industry can’t assume that it will be able to replicate the city centre approach that has worked so well in Kendall Square in Boston or King’s Cross in London. The “Petri dishes” of commercial innovation and cross fertilization in the APAC countries might well prove to be the more traditional science park locations.”
The report details the structural growth drivers for life sciences, accelerated by the impact of COVID-19, and their impact on real estate requirements. An ageing population, living longer and healthier lives, drives continued development of preventative treatments, prescriptive drug cures and innovation. An increased prevalence of lifestyle diseases, associated with the spread of wealth and sedentary lifestyles, adds to demand. A shift into preventative medicine and genetic R&D is being accelerated by the application of digital tech, artificial intelligence and machine learning, and life sciences firms are employing more data scientists. This transition is generating new start-up and SME businesses that, in turn, drive demand for specialist and appropriately located real estate.
The report profiles some life sciences developments that illustrate the trends it describes:
The report was funded and supported by a select group of ULI members participating in a steering group. Didobi was the research partner for the report, which was sponsored by AXA Investment Managers, Baker McKenzie, Charter Hall, IGIS Asset Management, Nuveen, and Savills.
Understanding the life sciences sector in Asia Pacific: the case for investment is available online at https://knowledge.uli.org/en/reports/research-reports/2021/understanding-the-life-sciences-sector-in-asia-pacific.
###
NOTE TO REPORTERS AND EDITORS:
About the survey
The report presents insights gained from market participants through a survey of 75 ULI Asia Pacific members, two round table discussions, and a series of telephone interviews with 19 industry experts, all held in August and September 2021. An extensive literature review, including reports from government, academia, real estate advisers, professional services businesses, media, and websites has also contributed to the knowledge base. More than 130 transactions between 2015 and 2021 were analysed to reveal patterns concerning the origins of and destinations for capital.
About the Urban Land Institute
The Urban Land Institute is a nonprofit education and research institute supported by its members. Its mission is to shape the future of the built environment for transformative impact in communities worldwide. Established in 1936, the Institute has more than 45,000 members worldwide representing all aspects of land use and development disciplines. For more information on ULI, please visit uli.org or follow us on Twitter, Facebook, LinkedIn and Instagram. ULI has more than 2,600 members in the Asia Pacific region. For more information on ULI Asia Pacific, visit asia.uli.org or follow us on Facebook, Instagram, LinkedIn and Twitter.
“With increasing volumes of capital searching for new investment opportunities across APAC, the Life Sciences sector offers huge growth potential, and presents a compelling investment opportunity for managers who are able to overcome the barriers to entry. AXA IM Alts intends to leverage its extensive knowledge of the Life Sciences sector in Europe, following its acquisition of the Kadans Science Partner platform – a market leading developer, owner and operator of science parks and lab offices – last year, in order to support the development of this emerging [and exciting] sector within the APAC region.”
“We are witnessing strong growth in the business of our life science sector clients. We do feel that the real estate investment managers can bring value to their business growth, particularly those life science players who want to strongly focus their growth capital and management attention to their core competencies”, said Dr. Isabella Liu, Head of the Life Science and Healthcare Group of Baker McKenzie. Mandy Lan, Special Counsel of the Real Estate Group of Baker McKenzie added that, “we are already handling several transactions where our real estate investment clients are adopting different investment and product strategies to seize the emerging opportunities in this sector.”
“The life science industry is expected to be a major growth sector in the region over the coming years with global biotechnology and pharmaceutical companies expanding their production capabilities across R&D, manufacturing and distribution. Our development, Innovation Quarter Westmead, is a prime example of a multi-disciplinary, purpose-built space that will facilitate flexibility and collaboration for our life science tenants. Industry research estimates life sciences is forecast to grow to be a $20bn plus sector in the years to come in Australia and Charter Hall is active in multiple core submarkets developing new facilities and acquiring existing investment assets. We see significant new growth potential and can also harness existing opportunities in our diversified $53 billion platform.”
“The Life Science industry in South Korea is growing more rapidly than ever over the past decade. Key players like Samsung Biologics, SK Biosciences and other pharmaceutical companies are expanding. However, the Life Science Real Estate industry is at a beginning stage. We are now trying to build up a database and making our own market report to look into this area. We believe that, considering the potentials and rapid expansion of industry, the demand for class A office and research center building will grow rapidly”
“We are delighted to be one of the sponsors of this report. Life sciences is a sector that continues to evolve and offer interesting opportunities to investors. Nuveen Real Estate’s global life science and healthcare real estate portfolio is well over US$1 billion, and we have a goal to grow it further.”
Don’t have an account? Sign up for a ULI guest account.